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Abstract 
Background: In Australia, the Home Medicines Review (HMR) is a nationally-funded program, led by 
pharmacists to optimize medication use for older people. A Medicines Conversation Guide was 
developed for pharmacists to use in the context of a HMR. The Guide aims to increase patient 
involvement and support discussions about: general health understanding, decision-making and 
information preferences, health priorities related to medicines, patient goals and fears, views on 
important activities and trade-offs. 
Objective: This study describes the development and feasibility testing of a Medicines Conversation 
Guide in HMRs with pharmacists and older patients. 
Methods: The Guide was developed using a systematic and iterative process, followed by testing in 
clinical practice with 11 pharmacists, 17 patients (aged 65+) and their companions. A researcher 
observed HMRs, surveyed and qualitatively interviewed patients and pharmacists to discuss feasibility. 
Transcribed recordings of the interviews were thematically coded and a Framework Analysis method 
used. 
Results: Pharmacists found the Guide to be an acceptable and useful component to the HMR, especially 
among patients with limited knowledge of their medicines. The Guide seemed most effective when 
integrated with the HMR and tailored to suit the individual patient. Some questions were difficult for 
patients to grasp (e.g. trade-offs) or sounded formal. Most patients found the Guide focused the HMR on 
their perspective and encouraged a more holistic approach to the HMR. From the quantitative survey, 
pharmacists found the Guide easy to implement, balanced and understandable. 
Conclusions: Pharmacists and patients reported the Guide fits with the HMR encounter relatively easily 
and promoted communication about goals and preferences in relation to medications. This study 
highlighted some key challenges for communication about medicines and how the Guide may help 
support the process of involving patients more in the HMR. 
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In Australia, the Home Medicines Review (HMR) is a nationally-funded program, led by pharmacists 
to optimize medication use for older people. A Medicines Conversation Guide was developed for 
pharmacists to use in the context of a HMR. The Guide aims to increase patient involvement and 
support discussions about: general health understanding, decision-making and information 
preferences, health priorities related to medicines, patient goals and fears, views on important 
activities and trade-offs. 
 
Objective 
This study describes the development and feasibility testing of a Medicines Conversation Guide in 
HMRs with pharmacists and older patients. 
 
Methods 
The Guide was developed using a systematic and iterative process, followed by testing in clinical 
practice with 11 pharmacists, 17 patients (aged 65+) and their companions. A researcher observed 
HMRs, surveyed and qualitatively interviewed patients and pharmacists to discuss feasibility. 




Pharmacists found the Guide to be an acceptable and useful component to the HMR, especially 
among patients with limited knowledge of their medicines. The Guide seemed most effective when 
integrated with the HMR and tailored to suit the individual patient. Some questions were difficult for 
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patients to grasp (e.g. trade-offs) or sounded formal. Most patients found the Guide focused the HMR 
on their perspective and encouraged a more holistic approach to the HMR. From the quantitative 
survey, pharmacists found the Guide easy to implement, balanced and understandable. 
 
Conclusions 
Pharmacists and patients reported the Guide fits with the HMR encounter relatively easily and 
promoted communication about goals and preferences in relation to medications. This study 
highlighted some key challenges for communication about medicines and how the Guide may help 
support the process of involving patients more in the HMR. 
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Polypharmacy; Older people; Patient involvement; Goals; Preferences 
 
1. Introduction 
Medicines reviews are a structured approach to ensure the medicines an older person is taking are 
appropriate. Similar pharmacy services and interventions exist internationally, for example, the 
UK's medicines management services1 and the USA's medication therapy management,2 although 
these services differ in several ways. In Australia, Home Medicines Reviews (HMRs) are 
government-funded and conducted by an accredited pharmacist in the patient's home. HMRs must be 
requested by a general practitioner (GP) and pharmacists receive a service fee of $219 upon 
completion of the HMR.3 In order to fulfill HMR remuneration requirements, the pharmacist writes a 
report to the referring GP based on which the GP formulates a medication plan. Comparatively, 
medication review services in the UK and USA differ in the following ways: location of the review is 
most often a pharmacy, review is requested by the dispensing pharmacist (UK), patient or other health 
care provider (USA), and the patient's GP is only included when there is a problem or it is considered 
necessary by the pharmacist (UK and USA). 
 
Polypharmacy (taking 5 or more regular medications) is one of the main reasons an older person is 
referred for a HMR.4 HMRs aim to resolve medication-related problems, encourage collaboration 
between the patient, pharmacist and GP, and promote patient wellbeing.5,6 According to the HMR 
Guidelines,7 the patient should be the main focus of the review reflecting the importance placed in the 
literature on a patient-centred approach to medicines use.9,11 Depending on the individual older 
patient's needs, this may lead to discussions about starting a medication, reducing the dose or stopping 
medications. However, there is currently no formal structure embedding this into clinical practice and 
the extent to which a patient is involved may vary considerably. 
 
An important part of optimizing medications in an older person is to evaluate the evidence on 
potential benefits and harms of medicines in light of his or her values, overall health and goals, and to 
prioritize medicines accordingly.8, 9, 10, 11, 12 This is part of a shift towards goal-concordant care 
for older patients and people with multi-morbidity, relying less on disease-specific 
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guidelines/treatment in decisions about health.13 When evaluating medications, clinicians and patients 
face complex trade-offs which can lead to an emphasis on preference-sensitive decisions.14,15There is 
evidence that taking into account patient goals and preferences improves outcomes16 and this seems 
particularly important for optimizing medicines for older patients.14 Even though patients vary in their 
preference for involvement in health decisions, most older people want their perspectives to be 
heard,17 so it is important for health care professionals to support communication and create 
opportunities for this. 
 
Tools to increase patient involvement in medical decisions have been developed, such as decision aids 
and question prompt lists. Reviews have found that decision aids can increase value concordant 
care18 and question prompt lists can support difficult discussions between clinician and patient (e.g. 
regarding prognosis).19 As most of these tools are single-disease focused, none support the complex 
decisions faced by an older person with comorbidities taking multiple medicines.14Furthermore, it is 
unlikely a single decision aid could incorporate the relevant evidence for multiple chronic conditions, 
medicines and combinations thereof,20 so a more flexible approach is needed. Emerging work in the 
context of serious illness and chronic conditions demonstrates promising results for clinical encounter 
discussion aids and conversation guides. They engage patients and clinicians in conversations about 
preferences and prirorities to increase patient involvement, support health decisions and create a 
quality interaction tailored to meet the needs of an individual.18,21 
This research group developed the Medicines Conversation Guide, a tool designed to support 
discussions about patient goals and preferences, and to improve the appropriate use of medicines. This 
is particularly relevant in the context of inappropriate polypharmacy. A feasibility study was 
performed to determine whether the Medicines Conversation Guide is suitable for further testing and 
focused on the following: acceptability, practicality and implementation. 
 
2. Methods 
2.1. Overview of development and testing 
Stage 1 of the development and testing of the Medicines Conversation Guide (Figure 1) consisted of a 
literature review, identification and adaption of an existing tool, iterative testing and critical review by 
experts in pharmacy, general practice, geriatric medicine and health communication/decision making. 
This was followed by a formal feasibility study in the context of the Home Medicines Review 





Fig 1. Flow chart of development and feasibility study 
 
2.2. Project team 
A multidisciplinary team guided the literature review, development and feasibility study. The team 
included experts in psychology (JJ, KMcC, CB), pharmacy (AM, DR), general practice (JD, LT), 
geriatric medicine (VN), epidemiology (LI), ethics (SC), statistics (KMcG) and representatives 
for consumers (JC) and NPS MedicineWise (AH). 
2.3. Ethical approval 
Ethical approval for the feasibility study was obtained through the Human Research Ethics Committee 
of the University of Sydney (Project No. 2015/935). 
2.4. Stage 1 
2.4.1. Literature review 
A narrative review of the literature into the challenges of shared decision makingand older patient 
involvement in decisions about polypharmacy and deprescribing (careful and supervised withdrawal 
of unnecessary or potentially harmful medications)22 was conducted.8 A framework was developed, 
describing the key steps of shared decision making for this context that draws together knowledge 
from the psychology, communication and decision-making literature. A systematic review of the 
literature was also conducted by authors of this paper to identify decision support tools (n = 22) for 
older people.20 Many of the tools were not considered appropriate for the aims of this study, as the 
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majority were not developed specifically for older people, and tended to focus on a single condition, 
rather than accounting for comorbidities. 
 
2.4.2. Medicines Conversation Guide 
In the search for existing tools, one was identified as suitable for adaptation in the context of this 
study. This tool was the Serious Illness Conversation Guide23 (created by Ariadne Labs), developed to 
support patient-clinician communication at the end-of-life where goal-concordant care and 
communication about values and preferences is important. It was designed for older people and 
encourages discussions around broader topics related to health, and what is most important for the 
individual, which is very relevant to the context of polypharmacy and deprescribing. The Serious 
Illness Conversation Guide was adapted for this study by removing any specific reference to 
prognosis and end-of-life care, changed the instructions for clinicians and revised some content to 
focus on medicines. The resulting Medicines Conversation Guide is a structured one-page tool 
designed to guide clinicians in conducting values and goals conversations around medicines. The 
wording is based on the original guide, which was tested in a patient population (patient/family 
advisory group and focus groups with patients, family members and clinicians). The key elements that 
are addressed include: general health understanding, decision-making and information preferences, 
health priorities related to medicines, patient goals and fears, views on important activities and 
making trade-offs for benefit/harm and quality/quantity of life. This intervention is intentionally 
designed not to influence people either towards or away from medicines, rather it aims to support 
goal-concordant care which could include well-informed decisions about stopping or reducing their 
medicines. 
 
2.4.3. Iterative testing and review process 
The first version was reviewed by GPs recruited through professional contacts and accredited 
pharmacists recruited from the Society of Hospital Pharmacists of Australia (accredited pharmacists 
specialist interest group) and the Australian Deprescribing Network (n = 8). They provided written or 
verbal feedback by email, phone or in person. The tool was tested informally in the context of the 
Home Medicines Review by an accredited pharmacist/researcher with 6 older patients who provided 
feedback over the phone to a researcher. 
The feedback from this iterative testing and review process was incorporated into version two of 
the Medicines Conversation Guide (referred to hereon as the Guide). The main revisions (Table 1) 
were: redesigning the format and structure, simplifying concepts such as quality of life and 
benefit/harm trade-offs, and rewording questions so they were easier to understand. Previous and 





Table 1. Summary of changes to the Medicines Conversation Guidea. 
Trigger for the change How the issue has been addressed Rationale/Justification 
TRADE-OFFS QUESTION V1: 
Would you be willing to accept a 
small increase in risk to your 
future health for less side effects 




difficult for patients to 
understand: “maybe 
could be simplified from 
a daughter's point of 
view to an oldie” (ID8, 
patient, female, age 89, 
daughter) 
• 
Pharmacists found the 
question awkward and 
clunky: “It is a mouthful 
and I reckon for some 
patients by the time you 
got to the end of the 
sentence they would've 
forgotten what it is.” 
(ID8, pharmacist) 
TRADE-OFFS QUESTION V2 
(truncated): 
Now we are going to work out what 
matters most to you, because 
different people value different 
things. 
PROMPT: If patient has 
unwanted side effects: 
- 
Some people think side 
effects such as aching 
muscles aren't a big deal 
- 
Some people hate having 
even mild side effects 
• 
In Version 2 the Trade-Offs 
question was modified to 
make it clearer for patients 
to understand and easier for 
pharmacists to ask and 
tailor to individuals. A 
preamble has been added to 
give context and the 
question is staged with 
options for the pharmacist 
to use at their discretion. 
FEASIBILITY STUDY 
Pharmacists and patients recognised 
the importance of the Trade-offs 
concept but needed a more effective 
way of discussing it: “what's the 
patient's objective?. They could die 
of old age tomorrow. So to them, 
quality is probably more important 
than, um, longevity, but not always” 
(ID8, pharmacist). 
LITERATURE/THEORY 
Consumer theory: patients need to 
recognise trade-offs between 
different options to clarify values 
and priorities, and link to 
preferences. 
• 
Important to involve 
patients in discussions 




concerned older patients 
may be unused to being 
involved in decisions 
about their health: "I 
find that they can't 
comprehend that kind of 
concept yet … they are 
very elderly patients 
who are so used to 
getting told by the 
doctors or pharmacists 
Question has been added to Version 
2 that encourages patient 
involvement, explores attitudes 




How do you feel about making 




To give pharmacists options, so 
questions sound less formal and 
natural. 
FEASIBILITY STUDY 
According to some pharmacists, this 
questioned supported patient 
involvement: “How do you feel 
about making changes to your 
medication? So by that stage I had 
summarised some of the information 
with him that I was going to suggest 
with the doctor … he said he was 
happy to discuss … them with the 
doctor, and that they'd be a shared 
decision” (ID5, pharmacist). 
 
LITERAUTRE/THEORY 
Previous study by our team [14] 
showed the importance of exploring 
patients' attitudes towards medicines 
and their openness to deprescribing. 
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Trigger for the change How the issue has been addressed Rationale/Justification 
what to do” (ID4, 
pharmacist). 
• 
Guide questions could 
sound too formal or 
scripted for patients: 
“sounding like you're 
sort of interrogating 
them" (ID1, 
pharmacist). 
Modifications have been made so 
the Guide can sound more informal 
and natural. An introduction has 
been added for pharmacists to 
introduce the discussion to patients. 
 
INTRODUCTION 
This guide is designed to facilitate 
an engaged discussion with older 
patients taking multiple medicines 
about their goals, preferences and 
priorities in relation to their 
medicines. 
• 
Prompts and alternative 
phrases have been provided 
as options 
to Guidequestions, in 
the Guide itself and 
additional intervention 
components (training 
module, strategies for 
common scenarios/barriers) 
FEASIBILITY STUDY 
“Overall the Guide needs contextual 
guidance to remind clinicians what 




A Delphi panel on a consensus 
definition of Advanced Care 
Planning [30] reported the need to 
prepare patients for goals and values 
discussions by stating the purpose 
and providing context. 
Training module will 
consolidate feasibility study 
findings to instruct pharmacists 
to use the Guideeffectively. 
• 
Guide questions could 
be too broad or 
tangential: “ some of the 
questions I found took 




Guide asked separately 
from the HMR: “I just 
did my HMR as I would 
normally do it and then 
I left the conversation 
guide to the end” (ID5, 
pharmacist). 
Training module is being developed 
to give strategies and instructions to 
pharmacists: 
• 
To relate broad responses 
to the patient's medicines or 




the Guidequestions with the 
HMR or ask questions 
when it's most relevant. 
FEASIBILITY STUDY 
To integrate the Guide with HMR 
use a checklist/bullet points: “Added 
[Guide] questions to my information 
collection sheet I use for HMR's” 
(ID8, pharmacist). 
Older patients preferred 
the Guidequestions interspersed with 
the HMR: “she didn't specify that 
those particular questions were from 
[Guide]. She just asked a series of 
questions in relation to what I was, 
… you know, when she was talking. 
And I answered it” (ID14, patient, 
female, age 77). 
LITERATURE/THEORY: 
The importance of training clinicians 
in communication, shared decision 
making and practical application of 
clinical encounter tools is well 
established [17, 19]. 
a Original Serious Illness Conversation Guide created by Ariadne Labs: A Joint Center for Health 
Systems Innovation (www.ariadnelabs.org) between Brigham and Women's Hospital and the 




2.4.4. Other intervention components 
Additional components to applying the Guide were developed including a summary table of 
recommendations from the HMR for the GP and the patient which included topics from the Guide. 
Strategies for pharmacists to use the Guide and to overcome any challenges in the conversation were 
developed in written form. These intervention components were developed in conjunction with the 
feasibility study based on what made the Guide more or less effective to implement. 
 
2.5. Stage 2 
2.5.1. Design 
The feasibility study design24,25 used mixed methods including observation, surveys and interviews 
with 11 pharmacists, 17 older patients and 4 of their companions through 17 HMR consultations. 
Besides a brief introduction to the overall purpose of the Guide, pharmacists were given minimal 
instructions on how to incorporate the Guide into the HMR to assess how flexible it was in real 
consultations. Pharmacists chose how to implement the Guide and which patients to use it with. 
 
Box 1 
Where the Medicines Conversation Guide fits in the HMR process. 
Step 
1 
Individuals are identified based on “clinical need” by their GP. This includes but is not 
limited to: a recent stay in hospital; significant change in medical condition, ability or 
medications; complex medication regimen 
Step 
2 
Referral of the patient is made to an HMR-accredited pharmacist 
Step 
3 
Pharmacist visits patient's home and conducts the medicines review and the pharmacist 
incorporates the Medicines Conversation Guide into their usual HMR practice 
Step 
4 
Pharmacist documents findings and recommendations in a report for the patient's GP 
Step 
5 
A medication plan is formulated by the GP and patient based on the pharmacist's HMR 
report. This step is at the discretion of the GP and may not always occur i.e. if no changes 
are needed 
 
2.5.2. Participants and recruitment 
Accredited pharmacists were recruited through two advertisements in the Australian Association of 
Consultant Pharmacy e-newsletter. Thirteen pharmacists completed the expression of interest form 
but 2 were unavailable during the data collection period. 
Older patients were referred for a HMR by their GP in the usual manner (see Box 1) and informed 
about the study by the accredited pharmacist who received the referral. If interested, patients were 
contacted by a researcher to explain the study and obtain consent. The HMRs were conducted as usual 
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in the patients' homes, if companions were present during the HMR they were interviewed over the 
phone together with the patient. 
 
2.5.3. Data collection 
A semi-structured interview schedule and quantitative survey was developed by a multidisciplinary 
team of experts (see Project team). The questions related to wording, clarity and appropriateness of 
questions were asked (e.g. “How did you find the wording of the Guide?”). The quantitative survey 
for pharmacists was based on previous work by this research group and asked about feasibility issues 
such as acceptability, content and ease of use. 
Basic demographic information was collected for pharmacists including years of experience with 
HMRs and number of HMRs in the past 12 months. To protect the confidentiality of older patients, 
only their information about age and gender were recorded. 
The researcher (KW) took notes during the HMR and added more detail and reflections afterwards. 
The telephone interviews with patients and pharmacists were conducted between 1 day and 2 weeks 
after the HMR and lasted 7–34 min. Interviews were audio recorded and transcribed verbatim with 
any identifying details removed. Pharmacists were followed up 6 months later to see they were still 
using the Guide. 
 
2.5.4. Data analysis 
Framework Analysis26 was used to organize the interview data and identify themes, with participants 
as rows and themes as columns. This thematic framework development involved a five-step process. 
First, upon completion of the interviews one researcher (KW) read through a subset of transcripts to 
identify salient themes. These themes along with the interview schedule formed the basis for the 
initial coding framework which was discussed and reviewed by a group of qualitative researchers 
(KW, JJ, CB, SCoh). Two researchers (KW, JJ) then independently reviewed another subset of 
transcripts, developed codes, and compared the data for similarities and differences in the data and 
coding. Researchers then discussed and established categories and overarching themes. Two 
researchers (KW, SCoh) independently summarised the themes and supporting quotes from each 
transcript with continuous discussion with other researchers. The observation notes were analyzed in 
the same way as the qualitative interview data and incorporated into the excel spreadsheet. 
When all of the data were coded, the framework was examined within and across themes and 
participants to identify relationships and themes. Rigour was addressed throughout by ensuring a 
detailed documentation of the analysis process; independent coding of a subset of transcripts, constant 




The majority of pharmacists (n = 11) were female (10/11) with an average age of 51, and most had 
been performing HMRs for 10 or more years (see Table 2). The older patients (n = 17) were a mix of 
male and female, ranging in age from 66 to 96 years old. 
 
Table 2. Characteristics of pharmacists and patients. 













Number of HMRs in past 12 months 
0–99 5 
≥100 6 











Themes have been broadly categorized as ‘positive’ or ‘negative’ in relation to key areas of 
acceptability, implementation and usability/practicality of the Guide. The main positive themes 
related to the Guide's format and content, integration of the questions with the HMR, and potential 
positive outcomes that it may improve the HMR. The negative themes pertained to how 
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the Guide was delivered, understandability of some questions and concerns that the HMR was an 
unsuitable setting for these types of discussions. Pharmacists differed in their approach to HMRs: 
some conducted more patient-centred and less structured, conversational reviews while others were 
more medicines-focused and very structured in their HMR interview. This influenced how useful 
pharmacists found the Guide and perceived barriers to implementation. 
 
3.1. Quantitative survey results 
From the quantitative survey results (Table 3), most of the pharmacists thought the tone of 
the Guide was neutral or positive (11/11), easy to understand (9/11) and completely balanced (9/11). 
The majority of the pharmacists also found the format of the Guide was simple (8/11) and easy to use 
(7/11). 
 
Table 3. Pharmacists' responses to quantitative survey. 
Question No. of Pharmacists n = 11 




The Guide was balanced: 
Slanted towards more medications 0 
Completely balanced 9 
Slanted towards less medications 2 








Question No. of Pharmacists n = 11 
Neither agree or disagree 2 
Disagree 1 
The Guide was easy to understand: 
Agree 9 
Neither agree or disagree 1 
Disagree 1 
Will continue to use the Guide in the future:a 
1–2 (not at all – slightly) 3 
3 (a medium amount) 3 
4–5 (a good deal – a great deal) 5 
a 1 = not at all, 2 = slightly, 3 = a medium amount, 4 = a good deal, 5 = a great deal. 
3.2. Positive 
3.2.1. Acceptability of the format and content 
Pharmacists generally found the Guide easy to use, the format was acceptable, flexible and of the 
right length (Table 3): "It's not lengthy, but it's relevant and it's practical” (ID6, pharmacist). Most of 
the older patients were comfortable answering the Guide questions and found them “easy to 
understand, I think I answered all the questions honestly and how I felt about it" (ID1, patient, female, 
age 84). Most patients found the Guide to be an appropriate addition to the HMR: "it all seemed to be 
part and parcel of the proper routine. I didn't think there was anything that didn't seem to fit in with 
the rest of it" (ID17, patient, male, age 88). 
 
3.2.2. Implementation of the Guide 
Based on the observations, how pharmacists delivered the Guide was an important indicator of its 
effectiveness and how useful pharmacists and patients perceived it to be, "works best if you can 
incorporate it with your [HMR] checklist" (ID8, pharmacist). Implementation was most successful 
when pharmacists introduced topics at relevant times and tailored questions to suit the patient and 
specific HMR (Table 4). 
 
Table 4. Summary of key findings with illustrative quotes. 
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Main finding Selected quotes 
Strengths The Guide was understandable and 
made sense to pharmacists and patients 
“They understood what I was asking, but also 
why” (ID3, pharmacist) 
“Shared decision making. I did so like that particular 
phrase.” (ID14, patient, female, age 77) 
“What [pharmacist] asked is 100% pertinent” (ID7, 
patient, male, age 82) 
“They seemed to … cover all aspects, and they 
seemed to be ... relevant” (ID10, patient, male, age 
96) 
Integrating with the HMR enabled 
the Guide to be more effective 
“So doing it in the body of my HMR, was good 
because … it followed through, you know, I tried to 
use it as I would normally do and just change the 
way I asked questions a little bit” (ID9, pharmacist) 
“Use it as a guide but just tailor it to the needs of the 
patient” (ID1, pharmacist) 
“I have modified it and incorporated it into my own 
interview guide” (ID11 pharmacist) 
“I was interspersing quite a bit of it. It probably 
added about … maybe 10 min to the complicated 
person” (ID3, pharmacist) 
The Guide introduced new concepts 
(goals and preferences) that focused the 
HMR on the patient's experience 
“Everyone's an individual and I think zeroing back 
on, what that person is going through is very 
important and I think those questions address that” 
(ID6, pharmacist) 
“What's the patient's objective? You know, they 
could die of old age tomorrow. So to them, quality is 
probably more important than, um, longevity, but not 
always” (ID8, pharmacist) 
“It was good to tell her what my main concerns, 
what was worrying me the most about my health. 
You know? Just to talk to someone about 
it. ‘Cos when you go to the doctor, they're so busy 
and … you're in and out, and … you can't, I can't 
open up to doctors properly”(ID12, patient, female, 
age 66) 
Limitations The Guide format was too structured 
and restrictive for some pharmacists 
“[HMRs] flow according, to their own riverbed, as it 
were. And every one of them's different. And trying 
to put a easy flowing conversation within the 
strictures of a scripted sort of … can have a little bit 
of a jarring tone” (ID11, pharmacist) 
“Maybe the bullet point is just ‘doctor awareness’. 
And that means, I've got to ask the person, do you 
think the doctor's aware of … the fact that your 
gout's not getting any better?” (ID11, pharmacist) 
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Main finding Selected quotes 
Some of the Guideconcepts/wording 
were difficult for patients to understand 
or unsuitable for a HMR 
“I find that they can't comprehend that kind of 
concept yet … because they are usually these are 
very elderly patient who are so used to getting told 
by the doctors or pharmacists what to do” (ID4, 
pharmacist) 
“the Sydney University questions were a bit 
academic and idealistic” (ID11, patient, male, age 
88) 
“Cause I work in some, probably quite low socio-
economic areas of [Sydney] and probably areas ... 
there's a lot of Australian but it's a more down-to-
earth English” (ID8, pharmacist) 
Pharmacist 
HMR style 
Some pharmacists conducted HMRs 
that were more structured, time-
conscious and focused on practical 
aspects of medicines 
“So my questions are often very … direct, like, you 
know, what difficulties are you having swallowing 
your medicines? Can you swallow them all whole? 
Or are there any that you need to crunch or chew 
up?” (ID5, pharmacist) 
“We don't have enough time to cover stuff that 
doesn't—that's not going to have any influence on 
the actual report in the end” (ID8, pharmacist) 
Some pharmacists conducted HMRs 
that were less structured, more 
conversational and patient-focused 
“Like I've always thought that I'm patient focused. 
I'm not drug focused particularly, which might sort 
of sound strange” (ID3, pharmacist) 
“So people may do more structured interviews than I 
do, but I try to get an empathy with them. But, um … 
you know, it helps. They give you more information” 
(ID2, pharmacist) 
“You can't ask them, oh tell me your pain score. 
They can, but I guess it doesn't … sit well. That 
rapport is not as good by asking … like the really 
formal … very health professional based question. 
And personally I prefer, the informal way” (ID4, 
pharmacist) 
 
Pharmacists reported the Guide could be naturally integrated with the HMR interview, and that this 
tended to be a more effective approach than asking the two sets of questions separately. Delivering 
the Guide flexibly and drawing upon relevant questions when the opportunity arose enabled 
the Guide to be more effective: “it wasn't in the order. I try to make it as natural as possible. So I, you 
know, while we're talking about this, how do you feel about that" (ID10, pharmacist). Another 
condition in which the Guide seemed more effectively implemented was when pharmacists modified 
questions to suit their language and communication style, “I didn't have to change it a lot. But I would 
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change it to fit in to my conversation” (ID2, pharmacist). Pharmacists discussed modifying the 
questions to meet the patient's needs and level of understanding. Pharmacists that conducted more 
patient-centred (rather than structured) HMRs reported finding it easier to adapt the Guide and 
incorporate it with their own HMR interview. 
Some of the older patients interviewed reflected the importance of interspersing the Guide questions 
with the pharmacist's HMR interview: “I think she was slipping them in …. I think a lot of the 
questions she asked were actually hidden through the whole thing” (ID15, patient, female, age 74). 
This also added to the perceived relevance of the Guide and contributed to how comfortable a patient 
was to answer. 
 
3.2.3. Practicality and usability 
Pharmacists discussed how the Guide was more suitable for certain patient characteristics or HMRs, 
with mixed responses. Some said it was most useful with patients who had less complex medicines 
reviews (i.e. no problems with their medicines), (n)one chronic conditions: “She just had such a 
simple regiment that, that I could use the Guide” (ID3, pharmacist). Others found it was especially 
beneficial for patients with multi-morbidities or complex chronic conditions on a high number of 
medicines: “the tool's definitely useful but to what extent the usefulness depends on the complexity of 
the case. It will be very useful for people who suffer from, for example, pain. Or depression. That type 
of chronic condition" (ID4, pharmacist). Some pharmacists noted the Guide may be useful in other 
contexts such as general practice with an integrated pharmacist, in primary care or multi-disciplinary 
setting delivered by a GP, nurse or allied health professional. 
Pharmacists reported the Guide was an acceptable addition in terms of timing and this was also 
reflected in the quantitative survey (Table 3) and observations. The majority of pharmacists said they 
would continue using at least some questions from the Guide, with some continuing to use 
the Guide when followed up 6 months later. 
 
3.2.4. Potential impact of the Guide and added value 
The findings from this study suggest that the Guide added value to the HMR process by introducing 
new concepts that facilitated communication between the patient, pharmacist and GP (Table 4). 
Pharmacists found the introduction of the concepts goals and preferences focused the HMR on the 
patient's experience not just the referring GP: “It puts you, more mindful of the patient's point of view, 
which is really what we're there for. Not just for GPs …” (ID10, pharmacist). This structured 
approach to facilitating patient involvement seemed to lead to a more collaborative HMR process, for 
instance fortifying recommendations with patient priorities: "then you can recommend that to the GP 
in your report to say Mr and Mrs Smith think that they would like to cut down on the number of 
medications" (ID1, pharmacist). Similarly, the ‘Trade-offs’ question facilitated discussion about 
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priorities around discontinuing medications, quality of life and longevity and importantly, 
communicating this to the GP: “opening the door ... is your GP actually aware of what's important to 
you to see whether or not they've had that conversation with the GP” (ID1, pharmacist). 
Older patients appreciated how the Guide encouraged a more holistic view on health: “it helped to 
focus the mind, in regards to health in general” (ID7, patient, male, age 82, partner), and provided the 
space to open up “other avenues for things … that are at the back of my mind" (ID14, patient, female, 
age 77). Some older patients reported they found it valuable to vocalize their concerns and to have the 
opportunity to do so. 
 
3.3. Negative 
3.3.1. Acceptability of the wording and understandability 
Some pharmacists highlighted problems with the wording of the Guide questions as sounding too 
formal when read out loud: "they look good but I think when I went to say them they weren't quite 
right" (ID8, pharmacist); "they're 65, they're not used to the formal way of questioning" (ID4, 
pharmacist) (Table 4). Pharmacists who had a less structured approach to HMRs found the Guide too 
restrictive. 
Some of the older patients stated that a few of the Guide questions were difficult to grasp the meaning 
of (Table 4). One patient who had a health background noted, “I suppose considering our age and 
education level it's probably easier for us than it might have been for someone else” (ID7, patient, 
male, age 82). Some older patients suggested the questions were too academic or complicated: 
“maybe could be simplified from a daughter's point of view to an oldie” (ID8, patient, female, age 89, 
daughter). 
Some pharmacists stated that the Guide questions were less suitable for patients who speak English as 
a second language or from a lower socio-economic background: “I can't ask these to most of the 
people … I deal with … They wouldn't understand it because, I do a lot of first generation immigrants 
…” (ID2, pharmacist). 
 
3.3.2. Implementation and perceived appropriateness of the Guide 
Some pharmacists reported asking the Guide questions separately at the beginning or end of the HMR 
interview. This often meant it didn't flow with the pattern of the HMR, issues weren't addressed when 
they came up and the questions were disconnected. These barriers were more often experienced by 
pharmacists that conducted more medicines-focused reviews, "I realized that it would have been a 
better experience for the patient if I kind of integrated the questions" (ID4, pharmacist). When asked 
at the beginning, it seemed too direct or upfront for older patients: “I just think as a whole, more of a 
general conversation. I know with Mum, it's easier to get information … if you're just talking, rather 
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than firing questions” (ID8, patient, female, age 89, daughter). One pharmacist suggested key words 
rather than questions may help integrate the Guide. 
 
Pharmacists suggested that concepts raised by the Guide were difficult for older patients to grasp 
because they were unfamiliar with being involved in health decisions. Similarly, pharmacists queried 
whether a GP should discuss goals and preferences with their patient instead: "If they're not used to 
having those discussions, are we the people during an HMR to start having these discussions or do 
the GPs need to be re-educated and then we need to re-introduce that question" (ID7, pharmacist). 
 
3.3.3. Practicality and usability 
Some pharmacists reported that some of the Guide questions were not suitable for the context of a 
HMR. Some pharmacists were tentative to use the terms ‘fears’ and ‘worries’ if the patient had not 
raised any themselves, due to concern the patient might become upset: "I think it could become a bit, 
… intimidating. ‘Cause there's lot of words that … might sound a bit scary" (ID10, pharmacist). A 
few pharmacists felt the Guide could lead the patient on tangents unrelated to medicines: "some of the 
questions I found took us off the track from medicines. And on to things like social or physio, and 
while I can give advice on dietary and stuff like that, I haven't got time … " (ID8, pharmacist). This 
could be difficult for pharmacists who were very medicines-focused and led structured HMRs without 
many open-ended questions. 
 
Although the Guide appeared to combine well with the HMR logistically, some older patients noticed 
the HMR seemed like a long time, but this varied depending on the pharmacists' HMR style and 
complexity of patient characteristics or medications. Some older patients stated the Guide questions 
were difficult to answer because of the high cognitive burden or because the problem felt too big to 
address: “I could have not answered more anything because, …I'm just in pain and somehow I feel 
that … I can't have any help. First of all I'm old also and, and I can't explain … properly” (ID6, 
patient, female, age 89). One patient felt the purpose of the Guide was not relevant to him: “I'm nearly 
88 … I concentrate on survival. I'm not looking for, I can't afford to look at, … picking up extra 
benefits out of life. I'm just a survivor” (ID11, patient, male, age 88). 
 
4. Discussion 
This paper describes the development and investigates the feasibility of the Medicines Conversation 
Guide as an additional component of HMRs for older people taking multiple medicines. The 
acceptability and implementation of the Guide was assessed from the perspective of pharmacists, 




Findings from the quantitative survey indicated the Guide was simple to implement, understandable, 
balanced and generally positive in tone. Feedback from pharmacists and older patients from the 
qualitative interviews showed the Guide to be an overall acceptable addition to the HMR. A few 
challenges were identified in terms of implementation and the Guide questions were difficult for some 
patients to understand. Some of the pharmacists thought a few of the questions in the Guideshould not 
be asked in a HMR rather should be addressed by the patient's GP. 
 
There were two main positive findings that highlight how the Guide could be successfully 
implemented in the context of HMRs. Firstly, delivery of the Guidequestions was most effective when 
pharmacists integrated questions with their usual HMR interview. Pharmacists who tended to conduct 
less structured HMRs in a naturally conversational style found the Guide easier to implement by 
adapting it to suit their communication style and the needs of the patient. Secondly, the Guidewas 
found to support communication about preferences and goals which was achieved by focusing the 
HMR and recommendations to the GP on the patient's priorities. This is significant, as recent findings 
from systematic reviews of polypharmacy interventions and medicines reviews have highlighted 
limited patient involvement. Patient-reported outcomes were not a priority for most RCTs of 
medicines reviews27 and few studies of pharmacist-led interventions discussed medication changes 
with the patient or provided sufficient information about patient involvement.28 
 
There were two main barriers to implementation of the Guide reported by some pharmacists and 
patients. Some pharmacists delivered the Guide separately from the rest of the HMR. Pharmacists 
differed in relation to this barrier, with pharmacists that conducted less structured reviews struggling 
to adjust to the strictures of the Guide layout/content. Pharmacists with a more structured HMR style 
had difficulty incorporating the Guide, so delivery could sound too formal or stilted. Patients reported 
the questions sounded interrogatory and appeared less comfortable answering questions when they 
were not integrated in the HMR interview. This barrier may be overcome by training and skill 
development which has improved the use of other tools such as clinical encounter guides and decision 
aids.18,29 Another possible way to overcome this barrier would be to integrate the Guide with the 
clinical environment by linking it with an electronic medical record or other digital system. However, 
this would require system level changes as HMRs are currently conducted in the patient's home with 
no standard process for conducting or reporting HMRs.30 
 
The second negative aspect related to perceptions of some pharmacists that the Guide was not suitable 
for a HMR context because certain topics such as changing medications and trade-offs should be 
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raised by a GP instead. For these pharmacists and patients, the acceptability of the Guide was lower. 
Even though pharmacists may have the opportunity during HMRs to discuss topics such as goals and 
preferences and make recommendations accordingly, this is not without challenges in clinical 
practice. Although the Guide was tested in the context of the existing HMR program, pharmacist 
participants recognized the applicability of the tool in other contexts – which may be explored in the 
future – delivered by GPs or practice nurses in the clinic setting or by staff in residential aged 
care facilities. Studies have found that discussions about goals and preferences are not embedded in 
routine care and clinicians may not be comfortable having these conversations for a number of 
reasons: being wary of overstepping professional boundaries, devolved responsibility, lack of 
communication between health professionals, and competing priorities.31,32 Although the difficulties 
should not be overlooked, starting this conversation is important. 
 
Furthermore, discussing patient goals and preferences comes naturally for some clinicians but can be 
difficult and counter-intuitive for others. HMRs are conducted heterogeneously and understanding 
how pharmacists are using the Guide in practice is helpful for implementation and further 
development of the intervention. Although the pharmacist HMR styles differed, all found 
the Guide useful to some extent and the majority stated they would continue to use the Guide in some 
form. These findings are informative as there are no guidelines available for developing or testing this 
type of intervention. To improve implementation of the Guide, these findings will inform a training 
module including components such as a flexible format, strategies for practical use/common barriers, 
role-play activities, guidance for prioritizing questions so as not to overburden any patients and 
suggestions for prompts or question alternatives that bring the conversation back to medications. 
This study is rare in that few other reported studies focus on older patients' preferences, goals and 
values in the context of medicines. The Medicines Conversation Guide is the first intervention to 
focus on optimizing medicines in older people and the role of preferences and goals in this context. It 
demonstrates the importance of beginning a meaningful conversation and creating the space to hear 
the patient's perspective. What follows after the HMR may involve iterative conversations that take 
place over multiple consultations, coordinated care with all health care providers,33 clinical tools 
(algorithms or decisions aids) to prioritize specific medications that can be safely reduced or 
stopped,22 and involving companions/family member(s) if preferred by the patient.34 
Limitations of this study include the small sample size and a predominantly female sample of 
pharmacists – although this gender ratio reflects the workforce population of accredited pharmacists 
to some extent.35 Pharmacists used the Guidewith an average of two patients so depending on the 
patient/HMR not all questions may have been asked. It was difficult for older patients to distinguish 
the Medicines Conversation Guide questions from the regular HMR interview and for many of the 
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patients it was their first HMR so they were unable to compare it to anything else. Lastly, 
recommendations made by the pharmacists were not followed through to the GP, meaning decisions 
made subsequently to the HMR are not known to us. 
 
Moving forward, showing that using the Guide in HMRs can effectively influence how GP's manage 
medication in older people, and results in better patient outcomes is the ultimate aim of this research 
program. The next steps are to focus on the GP's perspective to determine if the information from 
the Guide would improve the HMR report and help inform GP's management of their older patients. 
Following this, it would be useful to assess the impact of the Guide in a larger scale research project 
that captures rich data at each step of the HMR process involving the patient (and carer/family 
member), pharmacist and GP. 
 
5. Conclusions 
This research group developed the Medicines Conversation Guide designed to support discussions 
about patient priorities and goals in the context of medicines. The findings of the study described in 
this paper look promising in terms of increasing patient involvement and engaging older people in 
discussions about their medicines. To improve the value of the Guide, further consideration should be 
given to training clinicians about how to use the Guide with their patients and supporting pharmacists 
to tailor the Guide so that it is relevant and meets the needs of individual patients. The importance of 
follow-up with the patient's GP cannot be underestimated as well as promoting the patient's 
perspective in any decision about medicines. 
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